{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:00:53Z","timestamp":1793642453423,"version":"4.5.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>More than half of the patients treated with CD19-targeted chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL) do not achieve durable remission, which may be partly due to PD-1\/PD-L1\u2013associated CAR T-cell dysfunction. We report data from a phase 1 clinical trial (NCT02706405), in which adults with LBCL were treated with autologous CD19 CAR T cells (JCAR014) combined with escalating doses of the anti\u2013PD-L1 monoclonal antibody, durvalumab, starting either before or after CAR T-cell infusion. The addition of durvalumab to JCAR014 was safe and not associated with increased autoimmune or immune effector cell\u2013associated toxicities. Patients who started durvalumab before JCAR014 infusion had later onset and shorter duration of cytokine release syndrome and inferior efficacy, which was associated with slower accumulation of CAR T cells and lower concentrations of inflammatory cytokines in the blood. Initiation of durvalumab before JCAR014 infusion resulted in an early increase in soluble PD-L1 (sPD-L1) levels that coincided with the timing of maximal CAR T-cell accumulation in the blood. In\u00a0vitro, sPD-L1 induced dose-dependent suppression of CAR T-cell effector function, which could contribute to inferior efficacy observed in patients who received durvalumab before JCAR014. Despite the lack of efficacy improvement and similar CAR T-cell kinetics early after infusion, ongoing durvalumab therapy after JCAR014 was associated with re-expansion of CAR T cells in the blood, late regression of CD19+ and CD19\u2013 tumors, and enhanced duration of response. Our results indicate that the timing of initiation of PD-L1 blockade is a key variable that affects outcomes after CD19 CAR T-cell immunotherapy for adults with LBCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011287","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:11:47Z","timestamp":1698696707000},"page":"453-467","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Timing of anti\u2013PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre V.","family":"Hirayama","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-1773","authenticated-orcid":false,"given":"Erik L.","family":"Kimble","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn H.","family":"Wright","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-2215","authenticated-orcid":false,"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna M.","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2022","authenticated-orcid":false,"given":"Cecilia C. S.","family":"Yeung","sequence":"additional","affiliation":[{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"5Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gazeau","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Pender","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaney R.","family":"Kirchmeier","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Torkelson","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail N.","family":"Chutnik","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-4947","authenticated-orcid":false,"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4461","authenticated-orcid":false,"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"6Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"issue":"17","key":"2024012316212149200_bib1","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2024012316212149200_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024012316212149200_bib3","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024012316212149200_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"2024012316212149200_bib5","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"2024012316212149200_bib6","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"2024012316212149200_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"2024012316212149200_bib8","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2024012316212149200_bib9","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024012316212149200_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024012316212149200_bib11","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2024012316212149200_bib12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"2024012316212149200_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hon.128_2629","article-title":"Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B-cell non Hodgkin lymphoma: first results from the platform study","volume":"37","author":"Siddiqi","year":"2019","journal-title":"Hematol Oncol"},{"issue":"16 suppl","key":"2024012316212149200_bib14","doi-asserted-by":"crossref","first-page":"CT055","DOI":"10.1158\/1538-7445.AM2020-CT055","article-title":"Abstract CT055: phase 1\/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab (atezo) for the treatment of patients (pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson","year":"2020","journal-title":"Cancer Res"},{"issue":"11","key":"2024012316212149200_bib15","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: results from the phase Ib PORTIA study","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024012316212149200_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"19","key":"2024012316212149200_bib17","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"issue":"6","key":"2024012316212149200_bib18","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"355","key":"2024012316212149200_bib19","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"2024012316212149200_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1740774510382799","article-title":"A\u00a0modified toxicity probability interval method for dose-finding trials","volume":"7","author":"Ji","year":"2010","journal-title":"Clin Trials"},{"issue":"2","key":"2024012316212149200_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"27","key":"2024012316212149200_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024012316212149200_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"issue":"4","key":"2024012316212149200_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"7","key":"2024012316212149200_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2024012316212149200_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024012316212149200_bib27","doi-asserted-by":"crossref","first-page":"19712","DOI":"10.1038\/s41598-021-99311-y","article-title":"Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"key":"2024012316212149200_bib28","doi-asserted-by":"crossref","first-page":"110092","DOI":"10.1016\/j.intimp.2023.110092","article-title":"Dynamic changes of circulating soluble PD-1\/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma","volume":"118","author":"Lu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2024012316212149200_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/imm.13624","article-title":"Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma","volume":"169","author":"Chen","year":"2023","journal-title":"Immunology"},{"key":"2024012316212149200_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"issue":"3","key":"2024012316212149200_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"2024012316212149200_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"2024012316212149200_bib33","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"2024012316212149200_bib34","first-page":"1","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J\u00a0Immunother"},{"key":"2024012316212149200_bib35","doi-asserted-by":"crossref","first-page":"107796","DOI":"10.1016\/j.intimp.2021.107796","article-title":"Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: a systematic review and meta-analysis","volume":"96","author":"Balibegloo","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"15","key":"2024012316212149200_bib36","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024012316212149200_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2024012316212149200_bib38","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024012316212149200_bib39","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024012316212149200_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00262-018-2284-z","article-title":"Identification and characterization of an alternative cancer-derived PD-L1 splice variant","volume":"68","author":"Hassounah","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2024012316212149200_bib41","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"2024012316212149200_bib42","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024012316212149200_bib43","doi-asserted-by":"crossref","first-page":"e20210749","DOI":"10.1084\/jem.20210749","article-title":"In\u00a0vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue","volume":"219","author":"Li","year":"2022","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2024012316212149200_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","article-title":"Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade","volume":"41","author":"Pai","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"2024012316212149200_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood.2020009309","article-title":"Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL","volume":"138","author":"Zheng","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024012316212149200_bib46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T\u00a0cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"issue":"7926","key":"2024012316212149200_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/453\/2210522\/blooda_adv-2023-011287-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/453\/2210522\/blooda_adv-2023-011287-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T16:22:01Z","timestamp":1706026921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/453\/498528\/Timing-of-anti-PD-L1-antibody-initiation-affects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011287","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]}}}